Dopa.4U – Human iPS Cell-Derived Dopaminergic Neurons

Dopa.4U Manual Patch Clamp

The disease burden of current neurological disorders , including degenerative, genetic and neurotoxic, require the development of new standards for drug development.
To meet this need, Axiogenesis has developed human induced pluripotent stem cell (iPSC) derived dopaminergic neurons - Dopa.4UTM.

Dopa.4UTM represent an excellent in vitro model for efficacy, safety and toxicology studies with the following advantages:

  • Fully differentiated, primary-like morphological, electrophysiological and pharmacological characteristics
  • Long-term viability (> 50 days in culture)
  • Ready-to-use (just thaw and plate)
  • Quickly to implement: only 3 days pre-culture required post-thaw
  • Suitable for HTS
  • Applicable for drug development given presence of functional toxicity pathways (e.g. Parkinson’s Disease - MPP+, 6-OHDA)

Dopa.4UTM have been validated in the following assays and applications:

  • Immunocytochemistry    
  • Manual and automated patch clamp    [ Poster ]
  • Microelectrode array (MEA)    [ Poster 1 ] [ Poster 2 ]
  • Calcium transients    
  • Neurite outgrowth assay (high content analysis) 

For sales inquiries and data requests, contact us at This email address is being protected from spambots. You need JavaScript enabled to view it..

Next day delivery is available for both European and US customers. 

Dopa4U Elicited APDopa4U-Spontaneous AP

Fig. 1: Manual patch clamp recordings (current clamp) of Dopa.4UTM neurons.

Order Information Dopa.4U

Ax-B-HD02-2M: 2 x 10^6 frozen cells (vial)


Nattermannallee 1, Bldg S20
50829 Cologne
Germany –  (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)




Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter


Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10